The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

25 Jan 2024 07:00

RNS Number : 8282A
PureTech Health PLC
25 January 2024
 

25 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

24 January 2024

Number of ordinary shares purchased:

35,192

Highest price paid per share:

198.00p

Lowest price paid per share:

192.80p

Volume weighted average price paid per share:

195.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 18,884,863 ordinary shares in treasury and has 270,583,296 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 270,583,296 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

24/01/2024

08:29:27

815

192.8

XLON

00386861372TRLO0.1.1

24/01/2024

08:29:44

315

192.8

CHIX

00386861432TRLO0.1.1

24/01/2024

08:29:44

213

192.8

CHIX

00386861433TRLO0.1.1

24/01/2024

08:29:59

815

192.8

XLON

00386861483TRLO0.1.1

24/01/2024

08:30:43

916

192.8

XLON

00386861719TRLO0.1.1

24/01/2024

08:31:31

622

192.8

XLON

00386862022TRLO0.1.1

24/01/2024

08:34:33

515

192.8

XLON

00386862779TRLO0.1.1

24/01/2024

08:34:33

13

192.8

XLON

00386862780TRLO0.1.1

24/01/2024

08:39:41

528

192.8

XLON

00386864131TRLO0.1.1

24/01/2024

08:44:47

528

192.8

XLON

00386865524TRLO0.1.1

24/01/2024

09:32:54

6336

195

XLON

00386876245TRLO0.1.1

24/01/2024

09:34:07

173

195

CHIX

00386876729TRLO0.1.1

24/01/2024

09:34:36

96

195

CHIX

00386876791TRLO0.1.1

24/01/2024

09:37:02

2112

195.4

XLON

00386877399TRLO0.1.1

24/01/2024

09:37:08

528

194.8

BATE

00386877491TRLO0.1.1

24/01/2024

09:37:08

528

194.8

CHIX

00386877492TRLO0.1.1

24/01/2024

09:37:08

283

194.8

AQXE

00386877493TRLO0.1.1

24/01/2024

09:58:58

528

197

XLON

00386882071TRLO0.1.1

24/01/2024

10:00:28

193

197

CHIX

00386882619TRLO0.1.1

24/01/2024

10:00:28

291

197.2

CHIX

00386882620TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884053TRLO0.1.1

24/01/2024

10:08:52

1584

196.8

XLON

00386884055TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884054TRLO0.1.1

24/01/2024

10:08:52

342

196.6

TRQX

00386884056TRLO0.1.1

24/01/2024

10:16:28

1056

196.6

XLON

00386885232TRLO0.1.1

24/01/2024

10:16:28

481

196.6

XLON

00386885233TRLO0.1.1

24/01/2024

10:39:12

35

196.4

CHIX

00386889783TRLO0.1.1

24/01/2024

10:39:12

493

196.4

CHIX

00386889784TRLO0.1.1

24/01/2024

10:39:12

388

196.4

CHIX

00386889785TRLO0.1.1

24/01/2024

10:39:12

528

196.4

XLON

00386889787TRLO0.1.1

24/01/2024

10:39:12

575

196.4

XLON

00386889786TRLO0.1.1

24/01/2024

10:39:12

231

196.4

XLON

00386889788TRLO0.1.1

24/01/2024

10:39:12

148

196.4

XLON

00386889789TRLO0.1.1

24/01/2024

10:39:12

176

196.4

XLON

00386889790TRLO0.1.1

24/01/2024

10:39:13

35

196

BATE

00386889793TRLO0.1.1

24/01/2024

11:13:47

2112

196.4

XLON

00386895560TRLO0.1.1

24/01/2024

11:14:55

119

196.2

CHIX

00386895706TRLO0.1.1

24/01/2024

11:34:12

579

196.4

CHIX

00386898389TRLO0.1.1

24/01/2024

11:34:12

528

196.4

BATE

00386898390TRLO0.1.1

24/01/2024

11:34:12

2085

196.4

XLON

00386898391TRLO0.1.1

24/01/2024

11:48:28

528

196.8

XLON

00386901072TRLO0.1.1

24/01/2024

11:50:46

409

196.2

BATE

00386901394TRLO0.1.1

24/01/2024

11:50:46

2112

196.4

XLON

00386901395TRLO0.1.1

24/01/2024

12:20:02

528

197

XLON

00386906123TRLO0.1.1

24/01/2024

14:44:34

283

198

AQXE

00386943011TRLO0.1.1

24/01/2024

14:44:34

287

198

CHIX

00386943012TRLO0.1.1

24/01/2024

14:46:50

500

198

XLON

00386945228TRLO0.1.1

24/01/2024

14:46:50

154

198

CHIX

00386945227TRLO0.1.1

24/01/2024

14:46:50

52

198

TRQX

00386945229TRLO0.1.1

24/01/2024

14:46:50

28

198

XLON

00386945230TRLO0.1.1

24/01/2024

14:46:50

199

198

TRQX

00386945231TRLO0.1.1

24/01/2024

14:46:50

119

198

TRQX

00386945232TRLO0.1.1

24/01/2024

14:46:50

472

198

XLON

00386945233TRLO0.1.1

24/01/2024

14:46:50

56

198

XLON

00386945234TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945235TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945236TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTLIISFIS
Date   Source Headline
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.